Direct stenting versus direct stenting followed by centered beta-radiation with intravascular ultrasound-guided dosimetry and long-term anti-platelet treatment: results of a randomized trial: Beta-Radiation Investigation with Direct Stenting and Galileo in Europe (BRIDGE).
2004-08-04
Article
| Related Files |
|---|
|
(15358015.pdf, 0.3MB) |
|
Redirect to Publisher's version
(Publisher's version.url.txt, 44 bytes) |
Abstract OBJECTIVES: We sought to assess the efficacy of vascular brachytherapy (VBT) combined with stenting for the primary prevention of restenosis. BACKGROUND: Intravascular brachytherapy after stent implantation for de novo lesions has been abandoned for the present. We revisited this procedure by optimizing all procedural steps-the use of glycoprotein IIb/IIa blockers, direct stenting, adequate radiation coverage, avoidance of edge damage, source centering, intravascular ultrasound-guided dosimetry, and continuation of a dual anti-platelet regimen for one year. METHODS: The Beta-Radiation Investigation with Direct stenting and Galileo in Europe (BRIDGE) study is a multicenter, randomized controlled trial evaluating the long-term efficacy of VBT with P-32 (20 Gy at 1 mm in the coronary wall) after direct stenting. The primary end point was angiographic intra-stent late loss; secondary end points were six months binary restenosis and neo-intimal hyperplasia. Patients (n = 112) with de novo lesions (2.5 to 4.0 mm in diameter up to 15 mm long) were randomized to either VBT or no-VBT. RESULTS: At six months, intra-stent loss was 0.43 and 0.84 mm (p < 0.001) in the irradiated and control groups, respectively. Intra-stent neo-intimal volume was reduced from 36 mm3 to 10 mm3. However, in the irradiated group there were six late occlusions as well as eight restenoses outside the stented and peri-stented area at the fall-off dose edges of the irradiated area. Accordingly, the target vessel revascularization and major adverse cardiac and cerebrovascular events rates at one year in the VBT group (20.4% and 25.9%, respectively) were higher than in the control group (12.1% and 17.2%, respectively). CONCLUSIONS: Despite the optimization of pre-, peri-, and post-procedural factors and despite the relative efficacy of the brachytherapy for the prevention of the intra-stent neo-intimal hyperplasia, the clinical outcome of the irradiated group was less favorable than that of the control group.
- Male
- Aged
- Female
- Humans
- Middle Aged
- Coronary Angiography
- Europe
- *Stents
- *Ultrasonography, Interventional
- Platelet Aggregation Inhibitors/*therapeutic use
- Aspirin/therapeutic use
- Tunica Intima/pathology
- Phosphorus Radioisotopes/*therapeutic use
- Radiation Dosage
- Brachytherapy/*methods
- Hyperplasia/prevention & control
- Coronary Restenosis/complications/*prevention & control/radiography
- Primary Prevention/methods
- Ticlopidine/*analogs & derivatives/therapeutic use
- restenosi
- patient
- segment
- lesion
- stent
- radiation
- group
- vessel
- source
- trial
- treatment
- irradiation
- study
- length
- brachytherapy
- volume
- stenting
- occlusion
- edge restenosis
- control group